Skip to main content
Novo's once-weekly drug for type 2 diabetes approved by FDA

Novo Nordisk's once-weekly Ozempic, or semaglutide injection, was approved by the FDA for use in adult patients with type 2 diabetes as an adjunct to exercise and diet for the improvement of glycemic control.

Full Story: